FDA Approves Pirtobrutinib as First-Line Treatment for Most Common Leukemia

Chronic lymphocytic leukemia is the most common adult leukemia, and it predominantly affects older adults, making it directly relevant to aging and healthspan. The FDA's expansion of pirtobrutinib's approval to the first-line setting marks a significant advance in how this disease is managed, with implications for both survival and quality of life.

The approval was based on the randomized BRUIN-CLL-313 trial, which compared pirtobrutinib to bendamustine plus rituximab — a well-established chemoimmunotherapy regimen. Pirtobrutinib reduced the risk of disease progression or death by 80%, a striking magnitude of benefit. Median progression-free survival was not yet reached in the pirtobrutinib group, compared to 33.5 months in the chemotherapy arm. The overall response rate was also superior: 94% versus 81%.

What makes pirtobrutinib mechanistically distinct is its non-covalent binding to Bruton's tyrosine kinase (BTK), the only such drug approved in the U.S. Unlike covalent BTK inhibitors such as ibrutinib or acalabrutinib, non-covalent binding may retain activity even in patients who develop resistance mutations — a known clinical challenge with older BTK drugs.

Experts note that with modern targeted therapies, many CLL patients — especially older adults with comorbidities — may only receive one or two rounds of treatment in their lifetime. Selecting an optimal first-line therapy is therefore not just clinically important but may determine long-term disease control and functional capacity.

Pirtobrutinib's safety profile was consistent with prior data. Common side effects included upper respiratory infections, rash, and COVID-19. Grade 3/4 neutropenia occurred in 26% of patients, and serious adverse events in 28%. Prescribing warnings cover infections, bleeding, arrhythmias, hepatotoxicity, and secondary malignancies — factors clinicians must weigh when treating older, often comorbid patients.